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treatment delivery, optimal clinical outcome and meaningful 
reporting and comparison of treatments. 
In addition to high quality imaging and contouring guidelines, 
solid knowledge of radiological anatomy is a precondition to 
achieve best contouring standards. While this subject is 
recognized as one of the key competencies in the radiation 
oncology core curricula and training programmes [Eriksen JG, 
et al. Radiother Oncol 2012, www.acgme-i.org,], there is 
limited published data regarding the actual impact of the 
teaching interventions on contouring skills and the 
characteristics of the learning curve [Jaswal JK, et al. IJROBP 
2014, Cabrera AR, et al. J Am Coll Radiol 2011, Bekelman JE, 
et al. IJROBP 2009, D’Souza L, et al. BMC 2014]. 
Furthermore, published national surveys among radiation 
oncology residents and residency program directors indicate 
that there is room for improvement of training and 
evaluation of contouring competencies during residency [Jani 
AB, et al. Pract Rad Onc 2015, 12Jaswal JK, et al. IJROBP 
2013]. 
Contouring training should not be viewed as a process limited 
to the residency and fellowship programs and core-
curriculums. In a study evaluating the impact of prospective 
contouring rounds in a high volume academic centre, 36 % of 
cases required modification of contouring or written 
directives prior to treatment planning [Cox BW, et al. Pract 
Rad Onc 2015]. In a study of stereotactic body radiotherapy 
for lung cancer, the institutional peer-reviewers 
recommended major and minor changes of delineations in 23 
% and 37 % of 472 contoured structures, respectively [Lo AC, 
et al. J Thor Onc 2014]. In view of the rapid developments of 
imaging and radiotherapy delivery, accompanied by constant 
evolution and development of new contouring 
recommendations, the importance of continuous education of 
the experienced practitioners, mentors and trainers cannot 
be overemphasized. 
Research focusing on site-specific volumetric, topographic 
and qualitative aspects of contouring variation informs the 
educational activities in this field. The growing number of 
published inter-observer studies offers valuable resource to 
guide the training process. Limiting the learning to didactic 
and case-based instructions has improved knowledge scores 
and resident satisfaction in one study. However, this was not 
translated into improved contouring accuracy [D’Souza L, et 
al. BMC 2014]. In our experience, site-specific curriculum 
based on intensive sequence of didactic presentations, 
system-based instructions and hands-on contouring workshops 
represents an optimal strategy to achieve good learning 
results [Segedin B, et al. Submitted to Radiol Oncol 2016]. 
Feasibility and effectiveness of similar intensive educational 
interventions has been confirmed by others [Jaswal J, et al. 
IJROBP 2014]. 
These favourable early outcomes of teaching cannot be 
extrapolated on the long-term scale.Further evidence-based 
characterization of the learning curve is required to quantify 
the needs for continuous education and identify strategies for 
long term knowledge consolidation. Relative impact of the 
individual educational modules and qualifications of trainers 
on the learning outcome needs to be quantified, taking the 
tumour-site specific challenges into account. Development of 
training tools, including e-learning platforms and tools for 
objective assessment of contouring represent some of the 
main pre-requisites for future improvements in this field. 
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New physicists entering in to the speciality of brachytherapy 
normally undertake a formal training scheme in Medical 
Physics. Within the specialised field of brachytherapy the 
depth and breadth of training received can be dependent on 
the training scheme undertaken, training hospital’s expertise 
in brachytherapy, length of time dedicated to brachytherapy 
training and the assessment process.  
This presentation will summarise the key components of 
knowledge and experience a physicist should be expected to 
receive during their brachytherapy training and cross 
reference this to example training schemes. Several key 
questions need to be addressed when reviewing the training 
needs for image guided brachytherapy: Is additional training 
still required after completion of the formal training scheme? 
Are they appropriately focussed on image guided 
brachytherapy? 
It is important that any training gaps are identified and that 
measures are put in place to ensure that physicists have an 
understanding across all the components of image guided 
brachytherapy, have a full appreciation of the uncertainties 
and limitations within the brachytherapy pathway and of the 
systems used. 
Additional training resources will likely have to be explored 
to complement the core training schemes. Examples of 
available training resources will be presented and how they 
can potentially help facilitate the training and professional 
development of brachytherapy physicists. 
It is important that we ensure that opportunities for physicist 
training is not restricted and that physicists are allowed to 
develop their knowledge, understanding and skill set required 
for the modern image guided brachytherapy era. Training 
schemes need to continue to evolve and new training 
resources explored to complement formal training schemes 
and work based learning.  
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E-learning has the potential to deliver educational content to 
large numbers of learners world-wide. In 2008, Cook et al 
from the Mayo Clinic conducted a meta-analysis of 201 
studies of e-learning in the health professions. They found 
that internet-based instruction for medical professionals is 
associated with favorable outcomes across a wide variety of 
learners, learning contexts, clinical topics, and learning 
outcomes. Internet-based instruction appears to have a large 
effect compared with no intervention and appears to have an 
effectiveness similar to traditional methods. In a separate 
review in 2010, they identified that interactivity, practice 
exercises, repetition, and feedback improved learning 
outcomes.  
This talk discusses the potential of e-learning for teaching 
competency in target volume delineation (TVD). A crucial 
component of such a programme is automated assessment of 
contours with individualised feedback. The talk will compare 
conventional and novel methods for creating reference 
contours for TVD assessment, and conventional and novel 
metrics for automated assessment of TVD competency in 
individuals and groups of learners. The talk will also discuss 
the potential to investigate the impact of different 
instructional designs (e.g. live lectures, podcasts, annotated 
clinical cases, interactive demos) on TVD competency using 
quasi-experimental methodology. 
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A variety of therapeutic options are now available to cancer 
patients. It is recognised that significant biologic 
heterogeneity exists that may affect a patient’s likelihood of 
response to particular therapies and development of 
resistance on therapy. To be able to predict whether a 
patient will respond or not respond to a specific therapy is 
advantageous in streamlining patient management and 
minimising the costs of continuing therapy that is not working 
as well as minimising unwanted side-effects of such therapy.  
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Imaging currently play an important role in routine clinical 
care and clinical trials in triaging patients to appropriate 
management and in monitoring patients on therapy. In terms 
of treatment assessment it is essential for imaging markers to 
be consistent, reproducible and validated. Standardized 
response assessment based on morphological change, such as 
RECIST 1.1 is well established in the clinical trial setting 
although its limitations for therapies beyond standard 
chemotherapy are recognised e.g. immunotherapy, and for 
which alternative response criteria have been proposed. 
Computed tomography (CT) remains that most commonly 
performed imaging modality due to its high spatial resolution 
and its cost-effectiveness, but positron emission tomography 
(PET) and magnetic resonance imaging (MRI) have advantages 
in their capability to image beyond morphology.  
Measurement of glucose metabolism, cell proliferation, 
hypoxia, and vascularisation is now possible in clinical 
practice as well as quantification of their spatial variation, 
providing an imaging phenotype that is likely to be more 
beneficial than simple biomarkers e.g. size in predicting 
individual patient response to therapy. These imaging 
methods can also be integrated with genomic and 
pathological data allowing a comprehensive approach to 
address the clinical need towards individualisation of therapy 
in the future.  
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In personalized medicine, early prediction of pathologic 
complete response for locally advanced rectal cancer (LARC) 
patients is essential to tailor treatment. The standard 
treatment for LARC patients consists of preoperative 
chemoradiotherapy (CRT) followed by surgery, with a 
complete response being observed in 15-30% of the patients 
after the neo-adjuvant treatment. Overtreatment of 
complete responders could be avoided if an accurate 
prediction of pCR is available, by selecting a wait-and-see 
policy instead of surgery after CRT, and thereby reducing 
treatment related complications. Further treatment 
strategies based on the prediction of pCR include a 
radiotherapy boost after CRT for patients with good response 
to achieve a higher complete response rate, and additional 
chemotherapy after initial CRT for the worst responding 
patients. 
In recent years, [18F] fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET) imaging has been 
increasingly used for decision support, treatment planning 
and response monitoring during radiotherapy. Radiomics 
(www.radiomics.org; animation: 
http://youtu.be/Tq980GEVP0Y) is a high throughput 
approach to extract and mine a large number of quantitative 
features from medical images, characterizing tumor image 
intensity, shape and texture. The core hypothesis of 
radiomics is that it can provide valuable diagnostic, 
prognostic or predictive information. FDG-PET radiomics may 
therefore facilitate early and accurate prediction of tumor 
response to treatment to identify LARC patients eligible for a 
wait and see or organ preserving approach, or patients who 
may benefit from treatment intensification. 
This presentation will focus on the methodology of, and 
technical challenges in, the development and validation of a 
predictive PET radiomic model for pCR in LARC patients, 
illustrated with recent data. 
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In vivo treatment verification is highly desirable, especially 
but not only in particle therapy where uncertainties in the 
particle range can compromise the physical advantage of this 
treatment modality. Existing measurement techniques for 
range measurements exploit physical effects, in particular 
secondary radiation that is produced by the proton beam, for 
example through activation of positron emitters, or prompt 
gamma radiation. Also biological effects caused by the 
irradiation can be used for in vivo treatment verification, if a 
functional imaging method is available to visualize the 
effect. 
One prominent example for biology-driven range verification 
is an irradiation-induced change in contrast-enhanced MRI of 
the liver. A strong systematic decrease in uptake of the 
hepatobiliary-directed contrast agent Gd-EOB-DTPA has been 
shown in irradiated healthy liver tissue 6-9 weeks after 
irradiation [1-3] using different treatment modalities 
(brachytherapy, stereotactic body radiation therapy with 
photons and protons). The underlying mechanism seems to be 
based on a pro-inflammatory reaction of the irradiated liver 
tissue resulting in a downregulation of the Gd-EOB-DTPA 
uptake transporters and an upregulation of the respective 
excretion transporters [4].  
In a prospective clinical study, carried out at Massachusetts 
General Hospital in Boston (USA), we investigated whether 
MRI of the liver can be used for in vivo dosimetric verification 
already during the course of hypo-fractionated proton 
therapy of liver metastases (5 fractions within 2 weeks). In 
contrast to the previously found late changes weeks after the 
end of treatment that were seen in all patients, for the early 
Gd-EOB-DTPA enhanced MR imaging large inter-patient 
variations were found. For 10 patients, strong or moderate 
signal changes were detected for 2 and 3 patients, 
respectively. For 5 patients no dose-correlated early signal 
change was found at all. This qualitative scoring was 
consistent with a quantitative voxelwise dose to signal 
change correlation. The analysis of additional parameters 
that could potentially explain inter-patient variations (e.g. 
dose delivered at time of MRI scans, several timing 
parameters, liver function parameters and circulating 
biomarkers of inflammation determined from blood samples 
taken before and during treatment) revealed no clear 
correlation or trend with the strength of the signal decrease. 
Hence, irradiation-induced effects in the liver can be 
detected with Gd-EOB-DTPA enhanced MRI within a few days 
after proton irradiation in a subgroup of patients. As all 
patients possessed a signal decrease in late follow up scans, 
only the early dynamics of the liver response is influenced by 
these inter-patient variations. The reason for these large 
variations in early response is not yet fully understood and 
needs further investigation.  
This presentation will cover a brief overview of biological 
effects used for treatment verification and will then focus on 
the irradiation-induced signal change in Gd-EOB-DTPA 
enhanced MRI of the liver. The hypothesis for the biological 
mechanism, the available data for late and early MRI signal 
changes will be presented and open questions will be 
discussed.  
 
 
 
 
